Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands. An observational study showing significant symptoms´ improvement in patients with IBS-D treated with Gelsectan® in [...]
We are pleased to announce the launch of Rhinosectan® in its first market, Spain. Rhinosectan® is based on Xyloglucan, a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa, and it is specifically formulated to control and treat the symptoms of rhinitis and rhinosinusitis from different aetiologies, [...]
A new class of non-drug treatments for rhinitis of various origins is gaining momentum. Among them, Xyloglucan stands out as a natural substance with a well-defined mode of action: its mechanical barrier effect (1) can help in the control of the symptoms of rhinitis by preventing allergens, pathogens and pollutants [...]
Noventure is proud to announce that Medexport has signed an agreement for the distribution of Utipro Plus AF in Kazakhstan We are very grateful for their trust in us. It is really rewarding to expand into new territories with our products!! [...]
Noventure is proud to announce that Medexport has signed an agreement for the distribution of Utipro Plus AF in Kazakhstan We are very grateful for their trust in us. It is really rewarding to expand into new territories with our products!! [...]
Glad to inform that Noventure partnership with the Irish partner Pamex is growing! We are really happy to announce that Pamex is extending their distribution of Utipro Plus AF to the UK. We are very proud for their trust in our company and in our products, and we are sure [...]
Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April. Tasectan® AF is intended to restore the physiological functions of the intestinal [...]
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under the brand UrinCUR / Utipro plus and it is already present in Sweden, Norway and Finland, distributed as well by our partner RFSU. Utipro® Plus is a medical device intended for [...]
Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal [...]
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different [...]